| Patient | Duke Kahanamoku |
|---|---|
| Date of birth | 1959-08-24 |
| Identifiers | MRN HR-ML050-SYN; SSN (made up) 000-50-6847 |
| Document date | 2026-04-13 |
| Author | Kawika Lindgren-Morrison, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review after starting sacubitril-valsartan, carvedilol and empagliflozin. [S]
Mr. Kahanamoku returns two weeks after starting carvedilol and empagliflozin and twelve days after his first dose of sacubitril-valsartan, taken as planned 36 hours after the last lisinopril. He feels better: he walks up the slope near his office without stopping, the ankle swelling has gone, and he sleeps flat. He has had no lightheadedness, cough, genital itching or burning on passing urine. His home weight is steady at 93.5 to 94 kg. Coronary angiography last week showed an old complete blockage of the main artery at the front of the heart, with collaterals, and only mild narrowing elsewhere; the cardiologist advised that opening it would not help the scarred muscle. He is ready for the second iron infusion. [S]
| Element | Detail |
|---|---|
| Function | Walks uphill without stopping; NYHA class II to III |
| Medicine effects | No lightheadedness, cough or genital infection |
| Angiography | Chronic total occlusion of the proximal left anterior descending artery; mild disease elsewhere; no revascularization |
| KCCQ-12 | 56, from 38 |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain, palpitations, ankle swelling or lightheadedness |
| Respiratory | Negative | No cough; sleeps flat |
| Genitourinary | Negative | No genital itching or dysuria |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Aspirin 81 mg delayed-release oral tablet, one tablet daily | One tablet daily | Oral route | 2021-06-21 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2021-06-21 to 2026-03-16 | completed | S |
| Atorvastatin 80 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-16 | active | S |
| Metoprolol tartrate 25 mg oral tablet, one tablet twice daily | One tablet twice daily | Oral route | 2021-06-21 to 2026-03-30 | completed | S |
| Lisinopril 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2021-06-21 to 2026-03-30 | completed | S |
| Furosemide 40 mg oral tablet, one tablet every morning | One tablet every morning | Oral route | 2026-03-16 to 2026-04-27 | completed | S |
| Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet twice daily, first dose 36 hours after the last lisinopril | One tablet twice daily | Oral route | 2026-03-30 to 2026-09-28 | completed | S |
| Carvedilol 3.125 mg oral tablet, one tablet twice daily with food, starting the evening after the last metoprolol tartrate | One tablet twice daily with food | Oral route | 2026-03-30 to 2026-04-13 | completed | S |
| Carvedilol 6.25 mg oral tablet, one tablet twice daily with food | One tablet twice daily with food | Oral route | 2026-04-13 to 2026-04-27 | completed | S |
| Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating or drinking | One tablet daily, with sick-day rules | Oral route | 2026-03-30 | active | S |
| Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) daily | One-half tablet daily | Oral route | 2026-04-13 | active | S |
| Ferric carboxymaltose 750 mg (15 mL vial, 50 mg/mL) by intravenous infusion, two doses two weeks apart | Two infusions two weeks apart | Intravenous route | 2026-03-30 to 2026-04-13 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-13 | Body height | 185 | cm | S |
| 2026-04-13 | Body weight | 93.6 | kg | S |
| 2026-04-13 | Body mass index (BMI) [Ratio] | 27.3 | kg/m2 | S |
| 2026-04-13 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-04-13 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-04-13 | Heart rate | 74 | /min | S |
| 2026-04-13 | Respiratory rate | 16 | /min | S |
| 2026-04-13 | Body temperature | 36.6 | Cel | S |
| 2026-04-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-13 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-04-13 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-13 | Creatinine [Mass/volume] in Serum or Plasma | 1.16 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-04-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 69 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-04-13 | Glucose [Mass/volume] in Serum or Plasma | 96 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-04-13 | Magnesium [Mass/volume] in Serum or Plasma | 2 | mg/dL | 1.6-2.6 mg/dL | Normal | S |
| 2026-04-13 | Overall summary score [KCCQ-12] | 56 | {score} | S |
Vital signs recorded on 2026-04-13; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 118/72, pulse 74; weight 93.6 kg |
| Neck | Jugular venous pressure not raised |
| Cardiovascular | Regular rhythm; no S3; apical systolic murmur |
| Respiratory | Clear |
| Extremities | No edema; right radial access site healed |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Breathlessness on exertion for six weeks (paddling out, walking uphill, finishing his morning swim), with ankle swelling by evening and tiredness, five years after a heart attack; cause to be determined | resolved | confirmed | R06.09 | S — Synthetic presenting problem, resolved at the second visit when the echocardiogram and cardiology established heart failure with reduced ejection fraction. |
| Coronary artery disease with an old anterior myocardial infarction five years ago, treated with medicines; synthetic modern episode linked to the documented heart attack of 1952 | active | confirmed | I25.2 | S — Synthetic modern diagnosis; the 1952 heart attack remains D in the history. |
| Heart failure with reduced ejection fraction from ischemic cardiomyopathy (ejection fraction 30% with a thinned, akinetic anterior wall and apex), NYHA class III at diagnosis | active | confirmed | I50.22 | S — Synthetic modern diagnosis made at the second visit; no claim that he had heart failure in his lifetime. |
| Iron deficiency without anemia (ferritin 62 ng/mL, transferrin saturation 16%) | active | confirmed | E61.1 | S — Synthetic finding at the heart failure workup. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure and heart rate (seated and standing) | Every visit | Completed today | 118/72 mmHg, pulse 74; no orthostatic drop |
| Examination | Weight, volume status (jugular venous pressure, edema, lungs) and NYHA class | Every visit | Completed today | 93.6 kg; jugular venous pressure not raised; lungs clear; no edema; NYHA II to III |
| Laboratory | Metabolic panel (sodium, potassium, creatinine and eGFR) and magnesium | One to two weeks after starting or changing a diuretic, ARNI, MRA or SGLT2 inhibitor; then every three to six months | Completed today | About two weeks after sacubitril-valsartan and empagliflozin: sodium 137, potassium 4.5, creatinine 1.16 mg/dL (eGFR 69), magnesium 2.0 |
| Medication safety | Guideline-directed medical therapy: ARNI, evidence-based beta-blocker, MRA and SGLT2 inhibitor, toward target doses | Every two weeks during titration | Completed today | All four classes now started: spironolactone added and carvedilol raised today |
| Medication safety | SGLT2 inhibitor and ARNI: genital infection, volume depletion, hypotension and angioedema | Every visit | Completed today | None; sick-day rules reviewed |
| Survey | KCCQ-12 heart failure health status | At diagnosis, then every three to six months | Completed today | 56, from 38 |
| Imaging | Ischemic evaluation (coronary angiography) | At diagnosis of HFrEF with suspected coronary cause | Up to date | Done last week: chronic total occlusion of the proximal left anterior descending artery, mild disease elsewhere; no revascularization |
| Imaging | Echocardiogram | At diagnosis; repeat after three to six months of optimized therapy for device decisions, or with unexplained change | Not indicated | Diagnosis two weeks ago; repeat after three to six months of optimized therapy |
| Medication safety | Iron studies (ferritin, transferrin saturation) and intravenous iron | At diagnosis; after repletion and about yearly | Completed today | Second ferric carboxymaltose 750 mg infusion today |
| Examination | Primary-prevention ICD evaluation (and CRT if QRS is wide) | After at least 90 days of optimized therapy, and at least 40 days after a myocardial infarction | Due | After at least 90 days of optimized therapy |
| Referral | Cardiac rehabilitation for heart failure | When eligible: ejection fraction 35% or below, NYHA II to IV, six weeks of stable therapy and no procedure in six weeks | Due | Eligible from about six weeks after angiography and the last medicine start |
| Self-management | Self-care: daily weights, sodium, sick-day rules and symptoms to report | Every visit | Completed today | Weighs daily; less salted fish and shoyu; sick-day card given |
| Self-management | Culturally safe care: ʻohana involvement as he chooses; his own healing practices | Every visit | Completed today | He reviews decisions with his ʻohana at home as he chooses |
Goal progress:
Guideline basis: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction (2024); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026)
Follow-up: Review in two weeks with a metabolic panel (two weeks after spironolactone), a lipid panel and the KCCQ-12. Call for lightheadedness, vomiting or diarrhea (sick-day rules), or a weight change beyond the plan. Next scheduled visit 2026-04-27: two-week review, five days after the sick visit: kidney function and potassium, medicine doses, lipids, and cardiac rehabilitation adapted to the ocean. [S]